Fig. 9: FMT from SVHRSP mice mitigates dopaminergic neurodegeneration and motor impairments in rotenone-induced PD mice. | npj Parkinson's Disease

Fig. 9: FMT from SVHRSP mice mitigates dopaminergic neurodegeneration and motor impairments in rotenone-induced PD mice.

From: SVHRSP protects against rotenone-induced neurodegeneration in mice by inhibiting TLR4/NF-κB-mediated neuroinflammation via gut microbiota

Fig. 9

a Experimental design: mice in the Rot group received daily rotenone treatment for 3 weeks, whereas mice in the Rot + FMT group were first administered rotenone, followed by fecal microbiota freshly prepared from Rot + SVHRSP mice. Behavioral tests were conducted following 3 weeks of rotenone treatment. b Rotarod activity. c Gait performance. n = 11–14. d Immunostaining of TH+ neurons in the substantia nigra (SN) and striatum of mice. Scale bars represent 500 µm. e Quantitative assessment of the number of TH+ neurons in the substantia nigra pars compacta (SNpc). f Density of TH immunostaining in the striatum. g The protein expression levels of TH in the midbrain of mice were evaluated using western blot. h Electron microscopy showing the morphology of mitochondria in the SN. n = 4–5. *p < 0.05, **p < 0.01, ****p < 0.0001.

Back to article page